Copenhagen-based Biograil raises €20 million in a funding round for its innovative oral drug delivery device, with support from Verve Ventures and Megatrend Invest.
Biograil, a BioTech company in Copenhagen, has secured €20 million in a funding round to further develop its oral drug delivery device. The round was supported by investors including Verve Ventures and Megatrend Invest, with participation from HTGF. This funding will assist Biograil in advancing its proprietary BIONDD technology towards clinical development. The device aims to provide an alternative to injections for delivering therapeutics.
Who to call at Biograil, and when
A new round usually means Biograil is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Biograil raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Biograil, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Biograil. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Biograil
Location
Copenhagen, Capital Region Of Denmark, Denmark
About
Biograil is a Copenhagen-based BioTech company founded in 2019, focused on developing an oral device for delivering therapeutics that would otherwise require injection. They leverage proprietary BIONDD technology to create oral capsules that dissolve in the stomach and facilitate drug delivery into the tissue. The company aims to transform the market for injectable pharmaceutical products into convenient oral solutions. Biograil's team includes experienced entrepreneurs and R&D executives behind the first FDA-approved injection-moulded oral tablet.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Biograil raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
CopenhagenBiotechnologyHealth CareTherapeuticsPharmaceutical